ohm: any chance that DSMB's "continue" recommendation for S/C would give MHRA the confidence to approve Lero based on M/M meeting Oxford secondary endpoint? Wouldn't the "continue" recommendation give MHRA confidence that Lero is also working well in S/C patient population and essentially derisk approval based on M/M Oxford data? The UK would then be able to buy the entire 2020 Samsung Lero inventory and fix that loose end for CYDY.